WCM
NKTR icon

Weld Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Weld Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,739
Closed -$682K – 616
2020
Q3 		$682K Sell
2,739
-706
-20% -$222K 0.27% 127
2020
Q2 		$1.2M Buy
+3,445
New +$1.07M 0.47% 50

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Weld Capital Management's NKTR Position: Q4 2020 in Review

Weld Capital Management sold out of Nektar Therapeutics (NKTR) in Q4 2020, closing a stake of 2,739 shares — an estimated $682K sold.

Weld Capital Management first reported a position in NKTR in Q2 2020 and held it in 2 quarters. The position peaked at $1.2M in Q2 2020. 246 funds tracked by Wall St. Rank hold NKTR as of Q4 2020.

  • Weld Capital Management reported no remaining Nektar Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Weld Capital Management sold 2,739 Nektar Therapeutics shares in Q4 2020, an estimated $682K.
  • Weld Capital Management first reported a position in Nektar Therapeutics in Q2 2020 and held it in 2 quarters.
  • Weld Capital Management's Nektar Therapeutics position peaked at $1.2M in Q2 2020.
  • 246 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2020.

Based on Weld Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.